Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

ConferenceIM1240Positive

AI Analysis

Summary

Purple Biotech presented preclinical data for IM1240 at EACR 2026 demonstrating anti-tumor activity with favorable safety profile and broad therapeutic window.

Outcome Details

Preclinical data presented showing anti-tumor activity, favorable safety and pharmacokinetic profile, and broad therapeutic window

Importance:4/10

Sentiment:

0.60

preclinicalEACR 2026safetypharmacokineticsoncology

Related Companies

$PPBT

Read the original article

Published by yahoo_finance on June 11, 2026 11:00 AM

Read Original